SCHEMBL23645673

SCHEMBL23645673

COC(=O)C(C)Oc1ccccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
TSHR P16473 1/20 0.50
KMT2A Q03164 2/20 0.49
F9 P00740 1/20 0.45
PLAU P00749 1/20 0.45
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ACHE P22303 1/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
LY96 Q9Y6Y9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12635149 0.83 L3MBTL1 (0.50) LMNATSHRKMT2AALDH1A1GAA
SCHEMBL14092212 0.83 LMNA (0.42) LMNATSHRKMT2AALDH1A1HTR1A
SCHEMBL31108006 0.82 KMT2A (0.66) LMNATSHRKMT2AALDH1A1GAA
SCHEMBL12635150 0.82 KMT2A (0.66) LMNATSHRKMT2AALDH1A1GAA
SCHEMBL8037990 0.82 LMNA (0.52) LMNATSHRKMT2AALDH1A1GAA
SCHEMBL29039585 0.81 LMNA (0.46) LMNATSHRKMT2AALDH1A1GAA
SCHEMBL8275573 0.81 F9 (0.41) LMNATSHRKMT2AF9PLAU
SCHEMBL21415510 0.81 HPGD (0.56) TSHRKMT2AF9PLAUALDH1A1
SCHEMBL14783602 0.81 LMNA (0.51) LMNATSHRKMT2AALDH1A1GAA
SCHEMBL7812520 0.81 KMT2A (0.50) LMNATSHRKMT2AF9PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113087700-B Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2023-03-14 CN disclosed
US-11312724-B2 Spirocyclic tetrahydroquinazolines ASCENTAGE PHARMA (SUZHOU) CO., LTD. 2022-04-26 US disclosed
US-11312724-B2 Spirocyclic tetrahydroquinazolines ASCENTAGE PHARMA (SUZHOU) CO., LTD. 2022-04-26 US disclosed
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-29 US disclosed
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-29 US disclosed
WO-2021139748-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-15 WO disclosed
CN-113087700-A Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2021-07-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES KRAS, NRAS, HRAS LMNA 1228/4885TSHR 3233/4885KMT2A 1644/4885
US-11312724-B2 Spirocyclic tetrahydroquinazolines KRAS, NRAS, HRAS LMNA 1228/4885TSHR 3233/4885KMT2A 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.